Acellera Therapeutics and Psivant Therapeutics have entered a collaboration to accelerate the discovery and optimisation of small molecule drug candidates.
The partnership will combine Acellera’s AceForce technology with Psivant’s QUAISAR platform.
AceForce technology uses neural networks for precise protein-ligand potency prediction.
Acellera Therapeutics recently launched AceForce 1.0, a neural network potential (NNP) model providing quantum-level accuracy for predicting atomic interactions.
Psivant’s QUAISAR platform integrates quantum mechanics, molecular dynamics, and artificial intelligence (AI) to simulate protein motion and predict drug properties.
The companies aim to solve challenges in small molecule screening and drug design through rigorous lab testing and using advanced AI, machine learning, quantum chemistry simulations, and physics-based methods.
Acellera Therapeutics CEO Gianni De Fabritiis said: “This partnership demonstrates how we are pushing the boundaries of early-stage drug discovery by integrating quantum chemistry, machine learning and agentic AI.
“We are excited to collaborate with Psivant and harness the power of QuantumBind and PlayMolecule to pioneer new computational approaches to designing therapeutics.”
Co-financed by the European Regional Development Fund (FEDER), the collaboration combines predictive AI-driven insights with experimental workflows.
It also strengthens Acellera and Psivant’s position in the computational small-molecule drug discovery sector.
Psivant Therapeutics chief innovation officer Woody Sherman said: “By bringing together state of the art computational methods with our drug discovery expertise and in-house lab, we aim to deliver effective therapeutics for some of the most challenging disease targets.
“We look forward to combining Acellera’s cutting-edge AI and Quantum technologies with our validated QUAISAR platform, bringing innovative medicines to patients faster.”
Acellera Therapeutics accelerates drug discovery by combining AI-driven innovation with scalable computation, speeding up the development of future medicines and addressing unmet medical needs.
Psivant Therapeutics combines advanced computational algorithms with lab expertise to accelerate drug development.
The company uses advanced methods to identify candidates for synthesis and testing, focusing on breakthrough therapeutics for complex disease targets.
